Edwards Lifesciences Corp - 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Edwards Lifesciences Corporation on June 14, 2024. The filing addresses a specific corporate governance event regarding the departure of a senior officer and the appointment of a successor.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to personnel changes and does not contain financial performance data.
Material Changes
The primary material change reported is the retirement of Robert W.A. Sellers, Senior Vice President and Principal Accounting Officer, effective July 1, 2024. He is being succeeded by Andrew M. Dahl, who currently serves as Senior Vice President and Corporate Controller.
Management Commentary and Risks
Management confirmed that Mr. Dahl joined Edwards in February 2024. Prior to this role, he held positions at Medtronic PLC, Polaris Industries, and Deloitte & Touche LLP. The filing explicitly states there are no undisclosed arrangements regarding Mr. Dahl's appointment, no material interests in transactions requiring disclosure, and no family relationships with other directors or officers. No specific risks or contingencies related to financial operations were disclosed in this document.
Key Facts for Investor Verification
- Robert W.A. Sellers will retire as Principal Accounting Officer on July 1, 2024.
- Andrew M. Dahl is appointed as the new Principal Accounting Officer effective July 1, 2024.
- Mr. Dahl has been with Edwards since February 2024 and previously worked at Medtronic PLC.
- No financial results or guidance are included in this specific filing.